David A. Siegel Enochian Biosciences Inc Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.4 - $1.3 $9,280 - $30,160	-23,200 Reduced 41.13%	33,200 $18,000
Q1 2023 May 15, 2023	SELL	$0.91 - $1.31 $19,747 - $28,427	-21,700 Reduced 27.78%	56,400 $51,000
Q4 2022 Feb 14, 2023	SELL	$1.03 - $2.13 $34,093 - $70,503	-33,100 Reduced 29.77%	78,100 $80,000
Q3 2022 Nov 14, 2022	BUY	$1.7 - $2.86 $124,100 - $208,780	73,000 Added 191.1%	111,200 $201,000
Q2 2022 Aug 15, 2022	BUY	$1.93 - $8.73 $73,726 - $333,486	38,200 New	38,200 $74,000

14.7M

24K

19.1K

Ticker ENOB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,950,000
Market Cap $244M
Description
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.